Skip to content

Clinical Trial of Lupeol for Mild-moderate Acne

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02152865
Enrollment
25
Registered
2014-06-02
Start date
2009-12-31
Completion date
2014-05-31
Last updated
2014-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Keywords

medication

Brief summary

For the chemical lupeol isolated from eggplant, we applied it to one side of face, and applied vehicle control to another side for 8 -weeks. The study was performed in a 8-week, randomized controlled, split face fashion. Investigators evaluated safety and efficacy during baseline, 2 weeks, 4weeks, and 8 weeks after beginning of study.

Interventions

DRUGLupeol

Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.

Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over the age 15 who were clinically diagnosed with mild to moderate acne vulgaris

Exclusion criteria

* ; known pregnancy or lactation, any medical illness that might influence the results of the study, a previous history of oral acne medication or surgical procedures including laser treatment within 6 month and topical medication within 4 weeks of study enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Acne lesion counts as a measure of efficacy8 weeks after beginning of applicationsBoth inflammatory & non-inflammatory acne lesions of both of their facial sides

Secondary

MeasureTime frameDescription
Number of Participants with Adverse Events as a Measure of Safety and Tolerability8 weeks after beggning of applicationsAmong total patients enrolled in this study, number of patients either experiencing objective adverse events or subjective uncomfortableness were counted

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026